{"nctId":"NCT03289650","briefTitle":"Extended Release Tacrolimus vs. Twice-Daily Tacrolimus","startDateStruct":{"date":"2017-09-05","type":"ACTUAL"},"conditions":["End Stage Renal Disease","Rejection of Renal Transplant"],"count":29,"armGroups":[{"label":"Standard of care tacrolimus twice-daily","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tacrolimus"]},{"label":"Extended-release tacrolimus once-daily","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]"]}],"interventions":[{"name":"Tacrolimus","otherNames":[]},{"name":"Tacrolimus Extended Release Oral Tablet [Envarsus]","otherNames":["LCP-tacro"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Patients who are males or females aged 18-65 years. 2. Use of the following induction medications: basiliximab and rituximab. 2. Donors aged 18-65 years. 3. No prior organ transplant 4. Patients who are single-organ recipients (kidney only). 5. Women who are of childbearing potential must have a negative serum pregnancy test before transplantation and agree to use a medically acceptable method of contraception throughout the treatment period.\n\n6\\. Subject (recipient) is able to understand the consent form and give written informed consent\n\nExclusion Criteria:\n\n1. Delayed graft function (please see above).\n2. Known sensitivity or contraindication to alemtuzumab, EnvarsusÂ® XR, tacrolimus or MMF.\n3. Use of the following induction medications: basiliximab and rituximab\n4. Patient with significant or active infection.\n5. Patients with a positive flow cytometric crossmatch using donor lymphocytes and recipient serum.\n6. Patients with PRA \\> 40%\n7. Patients with current or historic donor specific antibodies\n8. Body Mass Index (BMI) of \\< 18 or \\> 35\n9. Patients who are pregnant or nursing mothers.\n10. Patients whose life expectancy is severely limited by diseases other than renal disease.\n11. Ongoing active substance abuse, drug or alcohol.\n12. Major ongoing psychiatric illness or recent history of noncompliance.\n13. Significant cardiovascular disease (e.g.):\n\n    * Significant non-correctable coronary artery disease;\n    * Ejection fraction below 30%;\n    * History of recent myocardial infarction.\n14. Malignancy within 3 years, excluding non-melanoma skin cancers.\n15. Serologic evidence of infection with HIV or HBVs-Ag positive.\n16. Patients with a screening/baseline total white blood cell count \\< 4,000/mm3; platelet count \\< 100,000/mm3; triglyceride \\> 400 mg/dl; total cholesterol \\> 300 mg/dl.\n17. Investigational drug within 30 days prior to transplant surgery.\n18. Anti-T cell therapy within 30 days prior to transplant surgery.\n19. Diagnosis of atypical-Hemolytic Uremic Syndrome (aHUS).\n20. Subjects transplanted with a Hepatitis C NAT-positive kidney.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant","description":"change in the mean eGFR from the baseline (2 weeks post transplant), 3 months (post transplant) , and 12 months (post transplant).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"1.71"},{"groupId":"OG001","value":"-2.19","spread":"1.77"}]}]}]},{"type":"SECONDARY","title":"Change in Subpopulations of T Cells From 2 Weeks Post Transplant Through 12 Months Post Transplant","description":"Blood, urine and kidney tissue analysis via serial flow cytometric immunophenotyping (includes regulatory T and B cell populations as well as immune functions).","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant","description":"Acute rejection of kidney transplant is determined via biopsy.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant","description":"Graft loss is determined via biopsy.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant","description":"Subject survival status is continually monitored via routine follow-up visits.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in Allograft Immunohistopathology Profile","description":"Tissue analysis via immunohistopathological staining and microscopic examination Moderate acute tubular necrosis =\\> presence of focal coagulative necrosis or infarction on histopathologic examination\n\nArteriolar hyalinosis grade 2 means: Replacement of degenerated smooth muscle cells by hyaline deposits in more than 1 arteriole, without circumferential involvement\n\nGlobal glomerulosclerosis \\>grade 2, means glomerulosclerosis affecting more than 50% of glomeruli in the biopsy sample\n\nIFTA : Interstitial fibrosis and tubular atrophy: Inflammation in 26% to 50% of scarred cortical parenchyma","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Leukopenia","Infections","BK Viremia","Malignancy"]}}}